Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC)
Both studies achieved secondary endpoint of improvements in bone mineral density with strong statistical significance
https://sg.finance.yahoo.com/news/mereo-biopharma-announces-phase-3-133100473.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.